astrazeneca
British pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition of Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). AstraZeneca, through a subsidiary, has completed the acquisition of all outstanding shares of Fusion as per the definitive agreement. The acquisition was executed under a plan of arrangement, with each share priced at $21.00 in cash at closing and an additional non-transferable contingent value right of $3.00 per share in cash payable upon the attainment of a specified regulato...
DPA International
British pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition of Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). AstraZeneca, through a subsidiary, has completed the acquisition of all outstanding shares of Fusion as per the definitive agreement. The acquisition was executed under a plan of arrangement, with each share priced at $21.00 in cash at closing and an additional non-transferable contingent value right of $3.00 per share in cash payable upon the attainment of a specified regulato...
DPA
British pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition of Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). AstraZeneca, through a subsidiary, has completed the acquisition of all outstanding shares of Fusion as per the definitive agreement. The acquisition was executed under a plan of arrangement, with each share priced at $21.00 in cash at closing and an additional non-transferable contingent value right of $3.00 per share in cash payable upon the attainment of a specified regulato...
DPA Breaking News
Shares in AstraZeneca were slightly higher on Thursday despite an update on the European Medicines Agency's website on Wednesday stating the regulator said that the approval for AstraZeneca's Vaxzevria had been withdrawn “at the request of the marketing authorisation holder.” AstraZeneca's Covid-19 vaccine was first given the nod by the EMA in January 2021. Within weeks, however, concerns grew about the vaccine's safety, when dozens of countries suspended the vaccine's use after unusual but rare blood clots were detected in a small number of immunised people. The EU regulator concluded AstraZe...
Euronews (English)
The pharma giant AstraZeneca has requested that the European authorisation for its Covid-19 vaccine be pulled, according to the EU medicines regulator. In an update on the European Medicines Agency’s website Wednesday, the regulator said that the approval for AstraZeneca’s Vaxzevria had been withdrawn “at the request of the marketing authorization holder.” AstraZeneca’s Covid-19 vaccine was first given the nod by the EMA in January 2021. Within weeks, however, concerns grew about the vaccine’s safety, when dozens of countries suspended the vaccine’s use after unusual but rare blood clots were ...
Euronews (English)
En una actualización publicada este miércoles en el sitio web de la Agencia Europea de Medicamentos ('EMA', por sus siglas en inglés), el regulador comunitario dijo que la aprobación de Vaxzevria de AstraZeneca había sido retirada "a petición del titular de la autorización de comercialización". El gigante farmacéutico cita como causa de la retirada****a nivel globalde su vacuna contra el COVIDuna caída de la demanda de sus dosis ante el desarrollo de múltiples opciones más adaptadas a las variantes del virus, lo que habría provocado un "excedente de vacunas actualizadas disponibles" desde la p...
Euronews (Spanish)
Pharmaceutical giant AstraZeneca reported its first quarter 2024 earnings on Thursday, seeing extremely robust earnings per share (EPS) and revenue growth. This was mainly due to continuously growing partner drug sales, as well as increasing demand for the company’s best-selling medicines. Total revenue soared 19% to $12,679 million (€11,818.1 million) year-on-year, primarily boosted by an 18% growth in product sales. Total revenue for oncology jumped 26%, with respiratory and immunology revenue rising 17% and cardiovascular, renal and metabolism revenue inching up 23%. Rare disease revenue ad...
Euronews (English)
The chief executive of pharmaceutical giant AstraZeneca could earn up to £18.7 million (€21.9 million) this year after shareholders approved a motion to increase his pay. Of the shareholders who voted on Thursday, around 64% were in favour of the decision, and 36% were against. Pascal Soriot’s base salary sits at around £1.5 million (€1.76), but he is now able to earn annual incentive payments worth up to 850% of this rate if he hits long-term targets. This compares to his previous incentive allowance of 650%. Since Thursday's vote, Soriot’s annual bonus could also increase to a maximum of 300...
Euronews (English)
Im Prozess um einen mutmaßlichen Corona-Impfschaden hat eine Frau aus Oberfranken einen Teilerfolg gegen den Hersteller Astrazeneca erzielt. Eine Zivilkammer des Oberlandesgericht (OLG) Bamberg verurteilte das Unternehmen zu einer umfassenden Auskunft über Nebenwirkungen seines Corona-Impfstoffs «Vaxzevria», wie ein Gerichtssprecher mitteilte. Der Zivilprozess gehört zu den ersten gegen einen Corona-Impfstoffhersteller in Deutschland. Das Unternehmen muss demnach Daten zu allen bekannten Wirkungen und Nebenwirkungen des Impfstoffs zur Verfügung stellen sowie zu sämtlichen weiteren Erkenntnisse...
DPA (German)
A woman in Germany has achieved an initial victory against the Anglo-Swedish drugmaker AstraZeneca in the trial over suspected harm caused by its Covid-19 jab. The civil case is one of the first in Germany against a coronavirus vaccine manufacturer. A civil chamber of the Bamberg Higher Regional Court, in Bavaria, ordered the company to provide comprehensive information about a possible side effects of its Covid-19 vaccine Vaxzevria. The company must disclose all known side effects of the vaccine as well as on all other findings that may be relevant "insofar as they relate to thrombosis with t...
DPA Breaking News
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら